Sarepta Therapeutics, Inc. (Nasdaq: SRPT) Posting Gains

Sarepta Therapeutics, Inc. – Nasdaq: SRPT

Shares of Sarepta Therapeutics, Inc. have been up almost 15% in early trading. SRPT is traded on the Nasdaq. On Monday SRPT closed at $31.26 and this morning shares have reached $37.40.

Cambridge, MA-based Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Sarepta Therapeutics Inc. secured, in 2016, an FDA accelerated approval for their drug Exondys 51. In the fourth quarter, Sarepta recorded $5.4 million in sales of Exondys 51.

Sarepta CEO Ed Kaye stated “We want to make sure that everybody knows the physicians and their patients are interested in Exondys. This [the $5.4 million in sales] is the proxy for that. It’s really not a bad number for a first quarter…”

Reports of bearish investor sentiment stem from a publicized dispute within FDA about the approval decision and reports of insurance companies denying DMD patients access to the drug. CEO Kaye acknowledges the reimbursement process for Exondys 51 has been challenging. Some patients have been rejected by their insurance carriers.

Reported sales for Sarepta Therapeutics Inc. have been declining annually since 2011 when it reported $47 million, in 2015 reported sales were just $1.3 million. Of the fourteen firms that rate SRPT, eight rate it as a “Strong Buy”, two rate SRPT as a “Buy”, and four rate it as a “Hold”.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.


Synergy Pharmaceutical Inc. (Nasdaq: SGYP) Soars on Positive Results

Synergy Pharmaceuticals Inc.; Nasdaq: SGYP

Shares of Synergy Pharmaceuticals Inc jumped more than 20% today in heavy trading. The New York City-based biotechnology firm trades on the Nasdaq under the ticker symbol SGYP. SGYP ended Thursday’s trading session at $4.74 and closed today up over 21% at $5.77.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced on December 22, 2016 (after market close) that positive top-line results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide, an investigational once-daily orally-administered compound, in 1,054 adult patients with irritable bowel syndrome with constipation (IBS-C).

Preliminary analysis of the data indicates that both plecanatide 3 mg and 6 mg doses met the study’s primary endpoint and showed statistical significance in the percentage of patients who were Overall Responders compared to placebo during the 12-week treatment period

Synergy Pharmaceuticals has pioneered discovery, research and development efforts around analogs of uroguanylin, a naturally occurring human GI peptide, for the treatment of GI diseases and disorders. Synergy Parmaceuticals has research, technical operations, and commercial offices in suburban Philadelphia. They have discovered, are developing, and control 100% worldwide rights to our proprietary uroguanylin analog platform that includes two lead product candidates – plecanatide and dolcanatide.

Plecanatide is their first uroguanylin analog currently being evaluated for use as a once-daily tablet for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Dolcanatide is their second uroguanylin analog currently being explored for ulcerative colitis.

Synergy Pharmaceuticals is covered by two firms and both give SGYP a “Strong Buy” rating. However the biotech company has yet to announce any revenues and has had negative EPS since it was listed on the Nasdaq in 2008.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

Ticker Symbol SGYP
Last Price a/o 4:00 PM EST  $               5.77
Average Volume 3.05 million
Market Cap $852.2 million
Shares Outstanding 179.8 million
Share Float 172.1 million
Shortable Yes
Optionable Yes
Inside Ownership 7.01%
Short Float 13.77%
Short Interest Ratio 7.78
Quarterly Return -15.50%
YTD Return -16.40%
Year Return -18.13%